Phase 3 study to evaluate the efficacy, safety, and tolerability of SAR440340/REGN3500/itepekimab (anti- IL-33 mAb) in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD)
| Research Studies » Patients with moderate-to-severe chronic obstructive pulmonary disease (COP |
|
|
|
Phase 3 study to evaluate the efficacy, safety, and tolerability of SAR440340/REGN3500/itepekimab (anti- IL-33 mAb) in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) |
